BR112018072887A2 - método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto - Google Patents

método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto

Info

Publication number
BR112018072887A2
BR112018072887A2 BR112018072887-0A BR112018072887A BR112018072887A2 BR 112018072887 A2 BR112018072887 A2 BR 112018072887A2 BR 112018072887 A BR112018072887 A BR 112018072887A BR 112018072887 A2 BR112018072887 A2 BR 112018072887A2
Authority
BR
Brazil
Prior art keywords
brain cancer
individual
compound
treatment method
cancer treatment
Prior art date
Application number
BR112018072887-0A
Other languages
English (en)
Inventor
Nicholas Greco Michael
John Costanzo Michael
Alan Green Michael
Peng Jirong
Lynn Wilde Victoria
Zhang Don
Original Assignee
Beta Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma, Inc. filed Critical Beta Pharma, Inc.
Publication of BR112018072887A2 publication Critical patent/BR112018072887A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

são divulgados métodos de utilização de derivados de 2-anilinopirimidina substituída e sais, solvatos ou composições farmaceuticamente aceitáveis, para o tratamento de câncer de cérebro, em particular câncer de cérebro metastático mediado por egfr.
BR112018072887-0A 2016-05-11 2017-05-11 método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto BR112018072887A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662334830P 2016-05-11 2016-05-11
US62/334,830 2016-05-11
PCT/US2017/032066 WO2017197062A1 (en) 2016-05-11 2017-05-11 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers

Publications (1)

Publication Number Publication Date
BR112018072887A2 true BR112018072887A2 (pt) 2019-03-06

Family

ID=60267544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072887-0A BR112018072887A2 (pt) 2016-05-11 2017-05-11 método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto

Country Status (17)

Country Link
US (1) US11052086B2 (pt)
EP (1) EP3454860A4 (pt)
JP (1) JP6908287B2 (pt)
KR (1) KR20190006991A (pt)
CN (1) CN109715164A (pt)
AU (1) AU2017264839B2 (pt)
BR (1) BR112018072887A2 (pt)
CA (1) CA3023228A1 (pt)
CO (1) CO2018012061A2 (pt)
EA (1) EA201892311A1 (pt)
IL (1) IL262801A (pt)
MX (1) MX2018013602A (pt)
PH (1) PH12018502360A1 (pt)
SG (1) SG11201809931YA (pt)
TW (1) TW201740951A (pt)
WO (1) WO2017197062A1 (pt)
ZA (1) ZA201807353B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
US10844045B2 (en) 2016-06-17 2020-11-24 Beta Pharma, Inc. Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
AU2018283289B2 (en) 2017-06-16 2021-03-25 Beta Pharma, Inc. Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN111100117B (zh) * 2019-12-18 2021-02-19 上海倍而达药业有限公司 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078409B2 (en) * 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
TWI510487B (zh) * 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2013014448A1 (en) * 2011-07-27 2013-01-31 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013106460A2 (en) 2012-01-09 2013-07-18 University Of Washington Through Its Center For Commercialization Compositions and methods for treating malignant astrocytomas
EP3778584A1 (en) 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
WO2016029839A1 (zh) * 2014-08-25 2016-03-03 四川海思科制药有限公司 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途
CN105461695B (zh) 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6709786B2 (ja) 2014-12-11 2020-06-17 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体

Also Published As

Publication number Publication date
PH12018502360A1 (en) 2019-03-25
AU2017264839B2 (en) 2021-08-05
MX2018013602A (es) 2019-08-22
US11052086B2 (en) 2021-07-06
JP6908287B2 (ja) 2021-07-21
CA3023228A1 (en) 2017-11-16
CN109715164A (zh) 2019-05-03
ZA201807353B (en) 2019-08-28
EP3454860A4 (en) 2020-01-15
JP2019514996A (ja) 2019-06-06
US20190365755A1 (en) 2019-12-05
SG11201809931YA (en) 2018-12-28
EP3454860A1 (en) 2019-03-20
IL262801A (en) 2018-12-31
WO2017197062A1 (en) 2017-11-16
KR20190006991A (ko) 2019-01-21
EA201892311A1 (ru) 2019-06-28
TW201740951A (zh) 2017-12-01
CO2018012061A2 (es) 2018-11-22
AU2017264839A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018006207A (es) Compuestos heterociclicos como inmunomoduladores.
EP3399982A4 (en) ANTI-EGFR ASSOCIATIONS FOR THE TREATMENT OF TUMORS
IL253979B (en) Methods, preparations and kits for cancer treatment
GB2541571A (en) Pharmaceutical compositions
MX2021007773A (es) Compuestos inhibidores de egfr.
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112018072887A2 (pt) método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto
CY1123592T1 (el) Αναστολεας κινασης aurora a
MX2018010993A (es) Derivados de icariina e icaritina.
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2018001369A (es) Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
IL268163A (en) Methods, compositions, and kits for treatment of cancer
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
EA201691896A1 (ru) Соединения и способы их применения
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors
WO2018081817A3 (en) Targeting microrna-101-3p in cancer therapy
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements